Global Prostate Cancer Disease Coverage Forecast and Market Analysis 2018-2024: Zytiga will face generic erosion, ensuring Xtandi remains the most valuable brand over the forecast period - ResearchAndMarkets.com

DUBLIN--()--The "Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering.

Prostate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to its large population size. While hormone-sensitive prostate cancer is well managed in terms of treatment options, the unmet need persists for patients with prostate cancer that is no longer responsive to hormonal manipulation. Newly approved therapies for castration-resistant prostate cancer are set to create a shift in the way that the disease is treated, while creating a competitive environment for new market entrants.

Market Snapshot

  • Zytiga will face generic erosion, ensuring Xtandi remains the most valuable brand over the forecast period.
  • ADT remains the most popular treatment choice for the majority of prostate cancer patients.
  • Label expansions into earlier treatment settings will help Xtandi combat growing competition.
  • Treatment may become more segmented as pipeline drugs with new mechanisms of action reach the market.
  • Drugs targeting non-metastatic CRPC will need to engage in rebate contracting in the US and in outcome-based risk-sharing agreements in the EU.

Key Topics Covered:

Forecast: Prostate Cancer

  • Executive Summary
  • Market Dynamics
  • Forecast And Future Trends
  • Market Definition And Methodology
  • Primary Research Methodology
  • Bibliography
  • Product Profile (Late Stage): Dcvac/Pca
  • Product Profile: Eligard
  • Product Profile: Firmagon
  • Product Profile: Jevtana
  • Product Profile: Lupron
  • Product Profile (Late Stage): Lynparza
  • Product Profile: Provenge
  • Product Profile (Late Stage): Rubraca
  • Product Profile (Late Stage): Tecentriq
  • Product Profile: Trelstar
  • Product Profile: Xofigo
  • Product Profile: Xtandi
  • Product Profile (Late Stage): Yonsa
  • Product Profile: Zoladex
  • Product Profile: Zytiga
  • Product Profile (Late Stage): Apalutamide
  • Product Profile (Late Stage): Darolutamide
  • Product Profile (Late Stage): Ipatasertib
  • Product Profile (Late Stage): Masitinib
  • Product Profile (Late Stage): Relugolix

Treatment: Prostate Cancer

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends

Epidemiology: Prostate Cancer

  • Executive Summary
  • Disease Background
  • Methodology
  • Forecast
  • Bibliography
  • Appendix: Additional Sources

Marketed Drugs: Prostate Cancer

  • Executive Summary
  • Product Overview
  • Product Profile: Eligard
  • Product Profile: Firmagon
  • Product Profile: Jevtana
  • Product Profile: Lupron
  • Product Profile: Provenge
  • Product Profile: Trelstar
  • Product Profile: Xofigo
  • Product Profile: Xtandi
  • Product Profile: Zoladex
  • Product Profile: Zytiga

Prostate Cancer Pricing, Reimbursement, And Access

  • Executive Summary
  • Market Context
  • Global Payer And Key Opinion Leader Insights
  • US Pricing
  • US Payer And Key Opinion Leader Insights
  • US Reimbursement
  • Japan
  • Pricing In The Five Major EU Markets
  • Five Major EU Markets Payer And Key Opinion Leader Insights
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Appendix

Pipeline: Prostate Cancer

  • Executive Summary
  • Clinical Pipeline Overview
  • Clinical Trial Design
  • Recently Discontinued Drugs
  • Product Profile (Late Stage): Dcvac/Pca
  • Product Profile (Late Stage): Lynparza
  • Product Profile (Late Stage): Rubraca
  • Product Profile (Late Stage): Tecentriq
  • Product Profile (Late Stage): Yonsa
  • Product Profile (Late Stage): Apalutamide
  • Product Profile (Late Stage): Darolutamide
  • Product Profile (Late Stage): Ipatasertib
  • Product Profile (Late Stage): Masitinib
  • Product Profile (Late Stage): Relugolix

For more information about this report visit https://www.researchandmarkets.com/research/njq3dm/global_prostate?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs